NextCell Pharma publishes Interim Report 3 2021/2022

July 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report.NextCells share is traded on Nasdaq First North Growth Market under the ticker"NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third quarter (2022-03-01 until 2022-05-31)

● Operating income amounted to 1 636 (906) TSEK.

● Operating result amounted to -9 307(-6 457)TSEK.

● Earnings per share* amounted to -0,27 (-0,19)SEK.

● Cash and bank amounted to 107 054 (150 754)TSEK.

● Solidity** amounted to 93,5 (96,9) %.

First nine months (2021-09-01 till 2022-05-31)

● Operating income amounted to 4 824 (3 074) TSEK.

● Operating result amounted to -25 991 (-20 079)TSEK.

● Earnings per share* amounted to -0,22 (-0,69)SEK.
‍

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523(34,056,943) shares. Average number of shares for the first nine months2021/2022: 34,379,523 (29,074,754) shares. Number of shares in NextCell as of May31, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the third quarter

● NextCell announced in early April that the stemcell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in Cellaviva's biobank, suffers from a serious blood disorder to be treated with stem cells at the Hematology Department at Rigshospitalet.

● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years
‍
● NextCell announced at the end of April that it is participating in a conference for world-leading cell therapies, the International Society for Cell and Gene Therapy 2022, in San Francisco and is represented by Mathias Svahn, CEO. Dr Svahn is a member of the Business Development and Finance Committee of ISCT.

● NextCell announced at the end of May that the company is presenting the ongoing clinical trial program with the drug candidate ProTrans lead cell therapy at the Advanced Therapies Congress in London on May 24-25.

● NextCell announced at the end of May that the European Patent Office(EPO) had issued an advance grant notice of the patent entitled "Allogeneic Composition" (publication numberEP3752598). The patent describes the method of manufacturing the drug candidate ProTrans and where the selection algorithm for selecting optimal cells and donors is the core. Patent protection is valid up to and i 2039.

Significant events after the reporting period

● NextCell announced in early June that all six children in the first part of the study with ProTrans. Patients will be monitored during the summer after which the safety of the treatment will be evaluated by an independent safety committee.

‍
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-07-2022 07:30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Instagram: https://www.instagram.com/cellaviva/

‍

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2020-02-21

The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study

NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to

Read more Read more

2020-02-10

Participates in innovation projects for cell-based products

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating

Read more Read more

2020-02-04

NextCell to present its progress at Swiss Nordic Bio 2020

NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich. Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about

Read more Read more

2020-01-31

Interim Report 1 2019/2020

NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31. First quarter (2019-09-01 until 2019-11-30) · Operating income amounted to SEK 1 222 087 (73 745). · Operating result amounted to SEK -3 755 926 (-5 440 809). · Earnings per share* amounted to SEK -0,20 (-0,38). · Cash and bank

Read more Read more

2019-12-11

Extended permission from the Medical Products Agency

NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory

Read more Read more

2019-12-04

Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported. "The results very are promising, even though there are only few patients and this part of the clinical trial was an

Read more Read more

2019-11-22

A part of Vision-driven Health

NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance. NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is

Read more Read more

2019-11-07

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and

Read more Read more